Tomorrow, Saturday, June 17th, coordinating study leader, Dr. Jan Hoffmann from King’s College in London, will present the primary parts of the final results from Chordate Medical’s pivotal clinical study PM007 at the American Headache Society Scientific Meeting. Chordate’s CEO, Anders Weilandt, is present in Austin, Texas.
“It’s very exciting, partly because it’s the first time the study’s final results are being presented at a conference, and also because it’s the first time the company is engaging in this type of activity in the USA,” says Anders Weilandt.
Chordate Medical CEO Anders Weilandt and Dr. Jan Hoffmann at American Headache Society Scientific Meeting in Austin, Texas.
In addition to Dr. Hoffmann’s lecture, Anders Weilandt has meetings with industry professionals and researchers over the weekend. The participants at the conference consist mainly of specialists in headache and migraine, with the majority being from the USA, but also including international visitors.
“The main focus is, of course, the presentation and capturing the expected interest it will generate. It’s also important to continue building networks within the industry represented at the conference and the associated exhibition.”